Olema Pharmaceuticals (OLMA) announced the FDA has cleared Investigational New Drug application for OP-3136, a small molecule that potently and selectively inhibits KAT6, a validated epigenetic target that is dysregulated in breast and other cancers. The company expects to initiate the Phase 1 clinical trial early next year.
"We are very pleased to have received notification from the FDA that OP-3136 may proceed into the clinic, said David Myles, Chief Discovery and Non-Clinical Development Officer of Olema Oncology.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com